Sudden cardiac death and dialysis patients

被引:223
作者
Herzog, Charles A. [1 ,2 ]
Mangrum, J. Michael [3 ]
Passman, Rod [4 ]
机构
[1] US Renal Data Syst, Cardiovasc Special Studies Ctr, Minneapolis, MN 55404 USA
[2] Univ Minnesota, Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA
[3] Univ Virginia, Dept Med, Charlottesville, VA USA
[4] Northwestern Univ, Dept Med, Chicago, IL 60611 USA
关键词
D O I
10.1111/j.1525-139X.2008.00455.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Dialysis patients have extraordinarily high mortality rates. The death rate for all US dialysis patients in 2004 was 230 per 1000 patient-years. Cardiac disease is the major cause of death in dialysis patients and accounts for 43% of all-cause mortality. In the United States Renal Data System database 62% of cardiac deaths (or 27% of all deaths) are attributable to arrhythmic mechanisms. The estimated rate of sudden cardiac death in US dialysis patients in 2002 was 7% per year. There are several plausible explanations for the special vulnerability of dialysis patients to sustaining sudden cardiac death. Obstructive coronary artery disease, coupled with diminished tolerance to myocardial ischemia (in the setting of myocardial fibrosis and left ventricular hypertrophy), rapid electrolyte shifts in hemodialysis patients, and derangements in autonomic function may all contribute to this heightened risk of sudden cardiac death. This review focuses on the epidemiology of sudden cardiac death in dialysis patients, underlying mechanisms of sudden death, and potential interventions to reduce the risk of sudden cardiac death in dialysis patients (including medical therapy and defibrillators). It is unlikely that one single therapeutic intervention will prevent sudden cardiac death in dialysis patients; but a more modest (and attainable) goal is the implementation of multiple strategies to reduce the risk of sudden cardiac death in this special high-risk population.
引用
收藏
页码:300 / 307
页数:8
相关论文
共 85 条
[71]   Immediate coronary angiography in survivors of out-of-hospital cardiac arrest [J].
Spaulding, CM ;
Joly, LM ;
Rosenberg, A ;
Monchi, M ;
Weber, SN ;
Dhainaut, JFA ;
Carli, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) :1629-1633
[72]   Inflammation in end-stage renal disease: The hidden enemy [J].
Stenvinkel, P .
NEPHROLOGY, 2006, 11 (01) :36-41
[73]  
Stevenson WG, 2005, CURR OPIN CARDIOL, V20, P42
[74]   Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study [J].
Takahashi, Akihiko ;
Takase, Hiroyuki ;
Toriyama, Takayuki ;
Sugiura, Tomonori ;
Kurita, Yutaka ;
Ueda, Ryuzo ;
Dohi, Yasuaki .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (09) :2507-2512
[75]   Symptomatic subclavian vein stenosis and occlusion in hemodialysis patients with transvenous pacemakers [J].
Teruya, TH ;
Abou-Zamzam, AM ;
Limm, W ;
Wong, L ;
Wong, L .
ANNALS OF VASCULAR SURGERY, 2003, 17 (05) :526-529
[76]  
United States Renal Data System, 2007, Am J Kidney Dis
[77]  
*UR REN DAT SYST, 2006, USRDS 2006 ANN DAT R
[78]  
US Renal Data System, 2002, USRDS 2002 ANN DAT R
[79]  
US Renal Data System, 2004, USRDS 2004 ANN DAT R
[80]   Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [J].
Wanner, C ;
Krane, V ;
März, W ;
Olschewski, M ;
Mann, JFE ;
Ruf, G ;
Ritz, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (03) :238-248